Abstract
The intratumoral microbiome (IM) associates with immune changes in the tumor microenvironment of preclinical lung cancer models; Escherichia exerts an immunostimulatory effect, reducing lung metastases. In patients (pts) with non-small cell lung cancer (NSCLC), the relationship between the IM and immune checkpoint inhibitor (ICI) efficacy is unknown. We sought to detect intratumoral bacteria in pts with advanced NSCLC using hybrid capture-based, next generation sequencing (NGS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
